Book a demo

Chemical intelligence powered by cypris.ai

Bromfenac sodium hydrate

sodium;2-[2-amino-3-(4-bromobenzoyl)phenyl]acetate;hydrate · also: XiDay, Xibrom, Remura, Duract, Bronuck, Xibrom QD

FormulaC15H13BrNNaO4
Mol. weight374.1658
PubChem CID23663409
InChIKeyBIYQNLJPABKADF-UHFFFAOYSA-M
SMILESC1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)[O-].O.[Na+]
1,272Patents
186Research papers
183Patents - last 3 years
10Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#AssigneePatents
1Gilead Sciences Inc101
2Clearside Biomedical Inc67
3Senju Pharmaceutical Co Ltd58
4Institució Catalana de Recerca i Estudis Avançats43
5UVA Licensing and Ventures Group37
6Genentech Inc26
7Rohto Pharmaceutical Co Ltd23
8Alcon Inc21
9Ascendis Pharma AS21
10Kala Bio Inc20

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#CodeAreaPatents
1A61KMedicinal preparations969
2A61PTherapeutic activity (drug indications)890
3C07KPeptides244
4C07DHeterocyclic compounds218
5G01NInvestigating / analysing materials162
6C12QMeasuring/testing involving enzymes125
7A61MDevices for introducing media into the body94
8A61F85
9C07CAcyclic and carbocyclic compounds85
10C12NMicroorganisms, enzymes62

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Most-cited patents

Patents ranked by forward citations reveal the foundational inventions the field continues to build on.

TitleYearAssigneeCited by
Gel for eye containing bromfenac sodium hydrate and preparation thereof2008WAN LIUYI6
Bromfenac sodium hydrate eye drops and preparation method thereof2013LOU FEI4
A kind of pharmaceutical aqueous eye drops and preparation method thereof containing bromfenac sodium hydrate2018Wuhan Leadpharm Technology Co., Ltd.3
A kind of bromfenac sodium hydrate thermosensitive type situ-gel eye drop and preparation method thereof2016Guangzhou Ren Heng Pharmaceutical Technology Co., Ltd3
Gel for eye containing bromfenac sodium hydrate and preparation thereof2013WEN GUANGHUI0

Where research is gaining momentum

Research themes ranked by publication activity show where scientific interest is accelerating around this compound.

#Research topicPapers
1Inflammatory mediators and NSAID effects3
2Coagulation, Bradykinin, Polyphosphates, and Angioedema2
3Anesthesia and Pain Management1
4Drug-Induced Hepatotoxicity and Protection1
5Glaucoma and retinal disorders1
6Ocular Surface and Contact Lens1
7Retinal Diseases and Treatments1

Technology trend analysis

Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.

See Cypris in action

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#AuthorAffiliationPapers
1James A. GowSpectrum Pharmaceuticals (United States)7
2L. David WaterburyEmergent BioSolutions (Canada)6
3Frank A. BucciBucci Laser Vision Institute5
4Joan Korth‐BradleyWomen's Health Research Institute5
5Sheryl DeCleeneWomen's Health Research Institute5
6James A. ForbesJohns Hopkins University4
7Nina R. Shah2
8Timothy R. McNamaraSpectrum Pharmaceuticals (United States)4
9William H. CevallosWomen's Health Research Institute4
10Curtis R. KellyAlcon (United States)3

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular composition of Bromfenac sodium hydrate?

Bromfenac sodium hydrate has the molecular formula C15H13BrNNaO4 with a molecular weight of 374.1658. Its canonical name is sodium;2-[2-amino-3-(4-bromobenzoyl)phenyl]acetate;hydrate, and it is also known by brand names including XiDay, Xibrom, Remura, and Duract.

Which organizations hold the most patents for Bromfenac sodium hydrate?

The leading patent assignees for Bromfenac sodium hydrate are Gilead Sciences Inc with 101 patents, Clearside Biomedical Inc with 67 patents, and Senju Pharmaceutical Co Ltd with 58 patents. Other significant holders include Institució Catalana de Recerca i Estudis Avançats with 43 patents and UVA Licensing and Ventures Group with 37 patents.

What are the main research topics associated with Bromfenac sodium hydrate?

The primary research topics include Inflammatory mediators and NSAID effects, Coagulation, Bradykinin, Polyphosphates, and Angioedema, and Retinal Diseases and Treatments. Additional focused areas encompass Anesthesia and Pain Management, Drug-Induced Hepatotoxicity and Protection, Glaucoma and retinal disorders, and Ocular Surface and Contact Lens research.

What does the patent literature reveal about formulation approaches for Bromfenac sodium hydrate?

Patent filings document diverse formulation strategies for Bromfenac sodium hydrate, including gel formulations for eye use, aqueous eye drops, and thermosensitive in situ-gel eye drop formulations. Representative patents include a gel for eye containing Bromfenac sodium hydrate and preparation thereof, eye drops with Bromfenac sodium hydrate, and pharmaceutical aqueous eye drops containing the compound.

What publication activity levels have been recorded for Bromfenac sodium hydrate research?

The aggregate covers 186 papers on Bromfenac sodium hydrate with 1272 total patents across all years. In the last three years, there were 10 papers and 183 patents filed. Key research contributions include comparative studies of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects, and work on European multicenter trials for prevention of cystoid macular edema after cataract surgery.

Turn any compound into a complete chemical intelligence landscape

Go beyond static compound data. Cypris resolves identities, patents, papers, and commercial signals into one AI-powered view - so your team can move from a single chemical question to a complete R&D, IP, and market landscape.

Schedule a free trial